Page last updated: 2024-11-12
cep 1612
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
CEP 1612: proteasome inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9939783 |
| MeSH ID | M0302629 |
Synonyms (15)
| Synonym |
|---|
| cep1612 |
| cep-1612 |
| phthalimide-(ch2)8ch(cyclopentyl)co-nitroarginyl-leucinal |
| 189036-01-9 |
| cep 1612 |
| unii-9k6u075027 |
| phthalimide-(ch2)8ch(cyclopentyl)co-arg(no2)-leu-h |
| 9k6u075027 , |
| 2h-isoindole-2-decanamide, alpha-cyclopentyl-n-(1-(((1-formyl-3-methylbutyl)amino)carbonyl)-4-((imino(nitroamino)methyl)amino)butyl)-1,3-dihydro-1,3-dioxo-, (n(s(s)))-(partial)- |
| 2h-isoindole-2-decanamide, alpha-cyclopentyl-n-((1s)-1-((((1s)-1-formyl-3-methylbutyl)amino)carbonyl)-4-((imino(nitroamino)methyl)amino)butyl)-1,3-dihydro-1,3-dioxo- |
| 2h-isoindole-2-decanamide, .alpha.-cyclopentyl-n-((1s)-1-((((1s)-1-formyl-3-methylbutyl)amino)carbonyl)-4-((imino(nitroamino)methyl)amino)butyl)-1,3-dihydro-1,3-dioxo- |
| 2h-isoindole-2-decanamide, .alpha.-cyclopentyl-n-(1-(((1-formyl-3-methylbutyl)amino)carbonyl)-4-((imino(nitroamino)methyl)amino)butyl)-1,3-dihydro-1,3-dioxo-, (n(s(s)))-(partial)- |
| Q27272662 |
| n-[(2s)-5-[[amino(nitramido)methylidene]amino]-1-[[(2s)-4-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]-2-cyclopentyl-10-(1,3-dioxoisoindol-2-yl)decanamide |
| AKOS040751074 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (4)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.76
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.76) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||